OR51E2 and melanoma: Among them is OR51E2 (Table S3), which is ectopically expressed in melanocytes [27] as well as in primary melanoma and melanoma metastasis [28] and whose activation has been shown to elicit an onco-suppressive effect in prostate carcinoma [29].